EMA Withdrawn: Leganto (rotigotine) — UCB Pharma S.A.

View source ↗

Summary

Leganto (rotigotine) has been withdrawn from the market by UCB Pharma S.A., affecting treatment areas including restless legs syndrome and Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Restless Legs Syndrome

Drugs mentioned

• Leganto (rotigotine)

Snippet

Status: Withdrawn. Therapeutic area: Restless Legs Syndrome;Parkinson Disease. MAH: UCB Pharma S.A.. Decision date: 14/12/2021